Organon (OGN) Acquires TOFIDENCE Apr 1, 2025 07:31AM
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. Apr 1, 2025 07:30AM
Halozyme (HALO) Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications Dec 30, 2024 06:31AM
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan Nov 26, 2024 12:50AM
Biogen (BIIB) Announces CFO Retirement Oct 28, 2024 08:33AM
View Older Stories

Oct 28, 2024 08:30AM Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
Jul 16, 2024 05:10AM Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Jun 11, 2024 08:45AM Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
May 29, 2024 07:02AM Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
May 16, 2024 07:31AM Biogen (BIIB) and Ionis (IONS) Report Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024 07:30AM Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024 07:30AM Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Mar 4, 2024 04:16PM Biogen (BIIB) Highlights New Data on Alzheimer’s and Parkinson’s Diseases
Mar 4, 2024 04:15PM Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
Oct 25, 2023 05:35PM Eisai, Biogen (BIIB) Injectable-At-Home Alzheimer's Drug Demonstrates Encouraging Potential
Sep 21, 2023 10:08AM Reata Pharma (RETA) Stockholders Approve Merger Transaction With Biogen (BIIB)
Aug 7, 2023 06:24AM SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDD
Aug 4, 2023 10:42PM FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Aug 4, 2023 10:41PM FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Jul 28, 2023 07:07AM Biogen (BIIB) to Acquire Reata Pharmaceuticals (RETA) for $172.50/Share, Approximately $7.3 Billion
Jul 28, 2023 07:05AM Biogen to Acquire Reata Pharmaceuticals
Jul 19, 2023 07:30PM Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Jul 7, 2023 05:33AM Biogen (BIIB) Announces FDA Granted Traditional Approval for LEQEMBI
Jul 6, 2023 08:00PM FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jun 30, 2023 04:09PM Biogen (BIIB) Presents New Data on SPINRAZA
Jun 30, 2023 04:06PM New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Jun 12, 2023 05:14PM Biogen (BIIB) Announces Board Changes
Jun 12, 2023 05:14PM Biogen Announces Changes to Its Board of Directors
Jun 12, 2023 05:30AM Biogen (BIIB) Announces FDA AdCom Voted Unanimously in Favor of Clinical Benefit of LEQEMBI for Treatment of Alzheimer's Disease
Jun 9, 2023 06:45PM FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Apr 28, 2023 02:00AM PureTech Announces Annual Results for Year Ended December 31, 2022
Apr 25, 2023 03:05PM Biogen (BIIB) Announces FDA Grants Accelerated Approval for QALSODY for SOD1-ALS
Apr 25, 2023 03:04PM FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Apr 25, 2023 03:04PM FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Apr 12, 2023 08:00AM Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Apr 12, 2023 08:00AM Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Apr 4, 2023 07:30AM Biogen Appoints Adam Keeney as Head of Corporate Development
Mar 31, 2023 05:50AM Biogen (BIIB) and Eisai Report Publication of Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab
Mar 30, 2023 07:31PM ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS
Mar 30, 2023 07:30PM Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Mar 30, 2023 07:30PM Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
Mar 30, 2023 07:30PM EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Mar 29, 2023 08:46AM Biogen (BIIB) Reports Promising Phase 1b Data for BIIB080
Mar 29, 2023 08:45AM New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
Mar 29, 2023 08:45AM New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease
Mar 22, 2023 08:31PM Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Mar 22, 2023 08:31PM Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Mar 16, 2023 06:33AM Biogen (BIIB) receives favorable EUR court ruling on TECFIDERA
Mar 16, 2023 06:30AM Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
Mar 16, 2023 06:30AM Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
Mar 14, 2023 07:30AM Biogen Appoints Chuck Triano as Head of Investor Relations
Mar 8, 2023 07:31AM Biogen (BIIB) Announces Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Board of Directors
Mar 8, 2023 07:30AM Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
Mar 8, 2023 07:30AM Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
Mar 8, 2023 06:30AM Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
View Older Stories